f45 glp 1 Functional Training and GLP-1 Medications GLP-ONE + Receptor Activator

FACT: Improved insulin sensitivity helps prevent excess glucose from being stored as fat, promoting lean muscle growth and fat loss

Glucagon-like peptide-1 receptor agonists (GLP-1RAs), approved for diabetes and obesity, have shown promise in modulating reward-related brain pathways, suggesting potential benefits in the management of AUD

doi:10.1001/jamanetworkopen.2024.57349

Results We identified 196,691 individuals with type 1 diabetes, 13% of whom were treated with adjunctive glucose-lowering therapy in addition to insulin

Employee demand data shows why pharmacy benefits teams are responding

Big news: The World Health Organization (WHO) has released its first global guideline on using GLP-1based medicines to treat obesity redefining obesity as a chronic, relapsing disease that deserves long-term care